Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2111455 Target Snapshot

CDK6/cyclin D1 · PROTEIN COMPLEX · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
607Compounds
121Assays
5Approved Drugs
976.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

CDK6/cyclin D1 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P24385. Start with breast cancer, then reuse UniProt P24385 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with breast cancer, then reuse UniProt P24385 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
breast cancer

CDK6/cyclin D1 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include PALBOCICLIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats CDK6/cyclin D1 as ChEMBL target CHEMBL2111455, mapped to UniProt P24385. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
CDK6/cyclin D1
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2111455
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P24385
G1/S-specific cyclin-D1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether CDK6/cyclin D1 is the right protein anchor across sources, using UniProt P24385 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why breast cancer is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameCDK6/cyclin D1
Target TypePROTEIN COMPLEX
OrganismHomo sapiens
UniProtP24385
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelG1/S-specific cyclin-D1
UniProt AccessionP24385
Component TypeProtein
Sequence Length295 aa

G1/S-specific cyclin-D1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as CDK6/cyclin D1, mapped to UniProt P24385. ChEMBL maps the protein component as G1/S-specific cyclin-D1. Sequence length is 295 aa.

Mapped IDP24385
Review nameCDK6/cyclin D1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

CDK6/cyclin D1 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
breast cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugPALBOCICLIB
Approved-linked Approved
breast carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPALBOCICLIB
Approved-linked Approved
breast neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugPALBOCICLIB
Approved-linked Approved
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugPALBOCICLIB
Approved-linked Approved
HER2 Positive Breast Carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPALBOCICLIB
Approved-linked Approved
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugPALBOCICLIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include PALBOCICLIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebreast cancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
7
Phase II
Assay Mix

Activity Type Distribution

IC50333.0
KI641.0
KD2.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5817327 10.22 Ki 0.06 Preclinical
CHEMBL5281860 10.19 Ki 0.064 Preclinical
CHEMBL4446357 10.1 Ki 0.08 Clinical
CHEMBL5994083 10.1 Ki 0.08 Preclinical
CHEMBL5833205 9.96 Ki 0.11 Preclinical
CHEMBL5774115 9.92 Ki 0.12 Preclinical
CHEMBL4750658 9.89 Ki 0.13 Preclinical
CHEMBL5281770 9.89 Ki 0.13 Preclinical
CHEMBL5746772 9.89 Ki 0.13 Preclinical
CHEMBL6047972 9.89 Ki 0.13 Preclinical
Distribution

pChEMBL Value Distribution

11
5.0
13
5.5
30
6.0
57
6.5
57
7.0
100
7.5
159
8.0
207
8.5
140
9.0
82
9.5
pChEMBL
Approved Drugs

Approved Drugs

ABEMACICLIB
CHEMBL3301610
Approved 2017
Properties Compare Identifier
RIBOCICLIB
CHEMBL3545110
Approved 2017
Properties Compare Identifier
PALBOCICLIB
CHEMBL189963
Approved 2015
Properties Compare Identifier
Assay Landscape

Assay Landscape

121
Total Assays
433
Tested Compounds
1
Assay Types
Binding — 121 assays, 433 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 100 397 8.3
cell-based format 18 9 7.5
assay format 3 27 6.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine